Ultragenyx Drug Fails Trial
Ultragenyx shares dropped significantly after its Angelman syndrome treatment failed a late-stage trial. The drug did not meet its main cognitive goals, prompting analyst downgrades and spending cuts.
Xurve View
Insights:
Xurve View